Kornimate/medical-research-clean huggingface dataset:
feasibility of virtual, tailored, music-based relaxation for anxiety in adolescent and young adult cancer survivors

Conditions: Anxiety

Summary: demonstrate the feasibility of conducting an eight-week, (45 min/week), theory driven, virtually-delivered, tailored music-based relaxation (timbre) intervention to decrease anxiety in adolescent and young adult (aya) cancer survivors with clinically-relevant anxiety.

initially sessions 7 and 8 were both body percussion; however, the 04feb2025 changed this to session 7 will be body percussion and session 8 will be selected by the participant. this will allow for more tailoring of the intervention.

Eligibility criteria:
inclusion criteria: * 15 - 39 years old * at least one month post cancer treatment * report clinically relevant anxiety in the past seven days (promis anxiety 4a scores ≥ 55)35 * speak/read english. exclusion criteria: * prognosis less than 3 months * documentation of significant hearing impairment * plan to receive surgery, radiation, or chemotherapy for cancer treatment during the study period * plans in place to begin new psychosocial (i.e., cognitive behavioral therapy14 or mindfulness-based stress reduction15) or pharmacological treatments for anxiety during the study. although, participants may continue psychosocial or pharmacological treatments for anxiety if the treatments were initiated at least eight weeks prior to study enrollment, the dose has not changed, and they report clinically relevant anxiety in the last week.
study of drug concentration of ondansetron and cefazolin in mothers and neonates

Conditions: Pregnancy Complications

Summary: this study proposes to look at the pharmacokinetics of two drugs (cefazolin and ondansetron) given routinely to pregnant women who are planning to deliver via cesarean section. the investigators will evaluate the metabolism of both drugs by the pregnant woman, the placental transfer over time, and the subsequent metabolism of the transferred drug in the neonate.

there is very little data on drug metabolism during pregnancy, and how it may differ from the non-pregnant woman. there is even less data on placental transfer of drug to the neonate when medications are given prior to delivery. this study proposes to look at the pharmacokinetics of two drugs (cefazolin and ondansetron) given routinely to pregnant women who are planning to deliver via cesarean section. the investigators will evaluate the metabolism of both drugs by the pregnant woman, the placental transfer over time, and the subsequent metabolism of the transferred drug in the neonate. the investigators hope to learn 1) the pk profile of both drugs in pregnancy, and how it differs from the non-pregnant woman, 2) the placental transfer of both drugs, and 3) the profile of neonatal metabolism of the drug that crosses the placental barrier.

Eligibility criteria:
inclusion criteria: adult participant: * age 18-45 years old * term pregnancy (37-42 weeks) * delivers by planned cesarean section, or unplanned, non-urgent cesarean section. * generally healthy * able and willing to sign informed consent neonatal participant: * male of female * 37-42 weeks gestation exclusion criteria: * adult:medical condition that would effect metabolism of the study drugs * known allergy to either study medication * use of medications in the last 48 hours that might induce or inhibit metabolism of ondansetron (e.g. barbiturates, fluconazole, erythromycin, etc.)

Keywords: bacteria infections
treatment of chronic gvhd of liver or lungs by ecp

Conditions: Chronic Graft-Versus Host Disease

Summary: chronic graft-versus-host disease (gvhd) is a major complication of allogeneic hematopoietic stem cell transplantation and the leading cause of death more than 2 years after transplantation.during the past 30 years survival of patients with chronic gvhd has not improved and steroids remained the most often used therapy. extracorporeal photoimmunotherapy (ecp)has shown to be efficacious in patients with gvhd. we propose a phase ii study to evaluate the safety and efficacy of ecp as adjunct first-line therapy in patients with newly diagnosed chronic gvhd of liver or lungs and need for systemic immunosuppression defined according to the nih consensus criteria.


Eligibility criteria:
inclusion criteria: * presence of at least one diagnostic clinical sign of chronic gvhd or an appropriate constellation of distinctive signs confirmed by biopsy or other relevant diagnostic tests * presence of liver or lung manifestations of chronic gvhd * indication for systemic immunosuppressive therapy defined according to nih consensus * no prior immunosuppressive therapy for chronic gvhd of the liver or lungs * adequate renal, hepatic, pulmonary and cardiac function * karnofsky performance score \>- 50% * women of childbearing potential must agree to use a reliable method of birth control for the duration of the study * signed written informed consent exclusion criteria: -

Keywords: hematopoietic stem cell transplantation graft-versus-host disease treatment
a randomized phase iii study of vitamins b6 and b12 to prevent chemotherapy-induced neuropathy in cancer patients

Conditions: Cancer

Summary: many types of chemotherapy may cause nerve damage as a side effect. this neurotoxicity can manifest as peripheral sensory neuropathy (characterized by numbness, tingling, or pain). the goal of this study is to determine the efficacy of the combination of vitamin b6 and b12 in preventing chemotherapy induced neuropathy.

neuropathy can be a significant side effect of chemotherapy using platinum compounds, taxanes, and vinca alkaloids. there is clinical and preclinical data that vitamin b6 and b12 may alleviate neuropathy in experimentally induced neuropathy in animal models, or clinical neuropathy such as diabetic neuropathy. this is a randomized phase iii study of the use of multivitamins with or without vitamin b6 and b12 to prevent or relieve neuropathic toxicity from chemotherapy in patients receiving chemotherapy. patients will be stratified by type of chemotherapy agent (3 groups), presence or absence of neuropathy at baseline, and randomized to receive placebo or vitamin b6/b12 supplementation.

Eligibility criteria:
inclusion criteria: 1. all patients, 18 years of age or older, with a cancer treated with any of the following drugs are eligible: * taxanes, vinca alkaloid analogs, heavy metals. * each patient will be allocated to the following 3 groups: * group 1 (heavy metals): patients treated with cisplatin (\>25 mg/m2/week dose intensity) or oxaliplatin * group 2 (taxane): patients treated with paclitaxel, docetaxel or abraxane * group 3 (vinca alkaloids): patients treated with vincristine and vinorelbine. 2. patients must have a life expectancy of at least 24 weeks. 3. patients must have a zubrod performance status of 0-2. 4. patients must sign an informed consent. 5. patients may have a grade 0 (chemotherapy naive) or 1 neuropathy (history of prior chemotherapy) prior to entry. exclusion criteria: 1. patients with symptomatic brain metastases are excluded from this study. 2. pregnant women or nursing mothers are not eligible for this trial. patients of child bearing potential must use adequate contraception. 3. patients may receive no other concurrent complementary medicines during this study. 4. patients with neuropathy induced diabetes are not eligible for this study 5. patients with severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections are not eligible for this trial.

Keywords: vitamin b-12 vitamin b-6 chemotherapy-induced neuropathy taxanes vinca alkaloid heavy metals neuropathy nerve pain
an observational study of infliximab injection in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis participants

Conditions: Spondylitis, Ankylosing; Arthritis, Rheumatoid; Psoriasis; Arthritis, Psoriatic

Summary: the purpose of this observational study is to evaluate the safety and effectiveness of infliximab injection under actual conditions of use in participants, and to learn more about its adverse events.

this is an observational, prospective (study following participants forward in time) study to assess safety and efficacy of infliximab injection under post-marketing use and identify problems related to adverse events in participants with ankylosing spondylitis (chronic inflammatory condition affecting the axial joints), rheumatoid arthritis (chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures), psoriasis (scaly skin rash) and psoriatic arthritis (a type of inflammatory arthritis associated with psoriasis). participants with rheumatoid arthritis will receive 6 doses of infliximab 3 milligram per kilogram (mg/kg) as an intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) at week 0, 2, 6 and will be observed for 30 weeks; and those with ankylosing spondylitis, psoriasis and psoriatic arthritis will also receive 6 doses of injection and will be observed for 24 to 30 weeks. efficacy will be evaluated by bath ankylosing spondylitis disease activity index (basdai), erythrocyte sedimentation rate (esr), c-reactive protein (crp), psoriasis area and severity index (pasi), swollen joint counts and tender joint count. participants' safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * participants with ankylosing spondylitis who did not show adequate response to general treatments and with increased serological indices related to severe axial symptoms and inflammation * participants with rheumatoid arthritis who show insufficient response to disease modifying antirheumatic drug (dmard) including methotrexate * participants with serious, active and progressive disease not previously treated with methotrexate or other dmard * participant with moderate to serious plaque psoriasis who are unresponsive, contra indicant or intolerable to the systemic therapy including cyclosporine, methotrexate or psoralen ultra-violet a (puva) * participant with active, progressive, psoriatic arthritis who have shown insufficient response to dmard treatment exclusion criteria: none

Keywords: spondylitis, ankylosing arthritis, rheumatoid psoriasis arthritis, psoriatic infliximab remicade
a study of computed tomography (ct) for evaluation of coronary artery blockages in typical or atypical chest pain

Conditions: Coronary Artery Disease

Summary: to compare computed tomography (ct) images (pictures) of the coronary arteries using the general electric (ge) lightspeed vct scanner with x-ray coronary angiography in patients with typical or atypical chest pain suspected of coronary artery disease (cad).


Eligibility criteria:
inclusion criteria: * the subject has typical or atypical chest pain suspected of cad and is referred for an elective coronary angiography. * the subject must be scheduled to undergo a cath procedure between 48 hours and 3 weeks post ccta procedure. * the subject must not undergo any cardiac interventional treatment between the 2 procedures. * the subject must have sinus rhythm with stable heart rate of ≤65 beats per minute (bpm) or if heart rate was \>65 bpm, the subject must agree to the use of beta-blocker(s) prior to the ct scan procedure to achieve stable heart rate of ≤65 bpm. exclusion criteria: * the subject had an established diagnosis of cad by a) previous cath, b) prior myocardial infarction confirmed by ecg, or c) prior revascularization (balloon angioplasty, stent placement, or cabg). * the subject had a known allergy to iodinated contrast agent, including but not limited to hives, anaphylactoid or cardiovascular reactions, laryngeal edema and bronchospasm. * the subject had impaired renal function with a serum creatinine level of 1.7 mg/dl (150 μmol/l) or above. * the subject had atrial fibrillation/flutter or any irregular heart rhythm considered by the investigator to interfere with temporal acquisition of cardiac ct images. * the subject had a resting heart rate of \>100 bpm and/or a resting systolic blood pressure of \<100mm hg. * the subject had an artificial heart valve(s). * the subject has had prior pacemaker or internal defibrillator lead implantation. * the subject's resting heart rate was \>65 bpm and beta-blocker therapy was contraindicated. * the subject had a contraindication to verapamil when beta-blocker therapy could not be administered. the subject had a contraindication to nitroglycerin. * the subject had evidence of ongoing or active clinical instability.

Keywords: ct coronary cardiac angiography x-ray cad chest pain
impact of variable types of preconditioning upon the inotrope score in adult patients, undergoing cardiac surgery

Conditions: Myocardial Ischemia

Summary: preconditioning (pc) of the heart occurs when brief exposure to a stimulus protects the heart from subsequent ischemia. pc stimulus may be (ischemic ; pharmacologic or physical).

preconditioning (pc) of the heart occurs when brief exposure to a stimulus protects the heart from subsequent ischemia. pc stimulus may be ( ischemic ; pharmacologic or physical) pharmacological pc may be induced by variable agents e.g. (sevoflurane ;isoflorane, opioids etc) ischemic pc includes local; remote and the idea is temporary interruption of blood supply to the organ so that liberation of protective mediators occurs. the liberated mediators have favorable effects not only upon the myocardium, but it extend to protect other organs against inflammatory activation; ischemia reperfusion injury inotropic score (is) is already an evident predictor of postoperative cardiac morbidity and mortality aim of the work: is to validate the impact of sevoflurane versus ischemic \& sevoflurane pc upon postoperative inotropic score in adult patient undergoing open heart surgery

Eligibility criteria:
inclusion criteria: * 18-60 years old * american society of anesthesiologists physical status ii and iii * patients scheduled for open heart surgery exclusion criteria: * emergency surgery * clinically significant kidney or liver disease * patients allergic to local anesthetic * patients with prolonged cardiopulmonary bypass time (\>120 min) * patients required intra-aortic balloon pump * postoperative hemodynamic instability (including the occurrence of serious arrhythmia) or bleeding that required surgical re-exploration

Keywords: myocardial preconditioning, inotropic score
comparison of surgical outcomes between avulsion fracture of the at and conventional atr--a retrospective study

Conditions: Avulsion Fracture of the Achilles Tendon; Achilles Tendon Rupture

Summary: to compare the surgical outcomes between avulsion fracture of the achilles tendon and conventional achilles tendon rupture, collected and analysed information of patients preoperatively and postoperatively.

include 30 patients with avulsion fracture of the achilles tendon and 30 patients with achilles tendon rupture underwent surgical treatment in our institute. collect and evaluate mri, vas, aofas, and ffi score preoperatively and postoperatively. finally explore the surgical outcomes between avulsion fracture of the at and conventional atr.

Eligibility criteria:
inclusion criteria: * patients with avulsion fracture of the achilles tendon or achilles tendon rupture exclusion criteria: * neuromuscular related diseases * other injuries of ankle joint
primary progesterone therapy for operable breast cancer

Conditions: Breast Neoplasms

Summary: the purpose of this study is to test the effect of primary progesterone on overall and disease free survival in women with operable breast cancer. the study addresses two issues related to breast cancer surgery: * circulating progesterone at the time of surgery might counteract the detrimental effect of estrogen on survival of women with operable breast cancer. * events at the time of surgery may have an impact on the natural history of breast cancer

this protocol addresses the issue of pre-operative hormone manipulation in women with operable breast cancer. the study has been designed after careful review of literature to assess the effect of unopposed oestrogen at the time of surgery and collect evidence that events at the time of surgery may have impact on the long-term survival of breast cancer patients. the meta-analysis of 37 studies on timing of surgery during the menstrual cycle showed a 15% + 3 improvement in survival for women who had undergone surgery during the luteal phase of their menstrual cycle. three of the 37 studies where progesterone levels were estimated at the time of surgery showed 52% + 26 improvement in survival when circulating progesterone were \> 1.5 ng/ml. the study aims to produce luteal milieu by injecting hydroxy- progesterone 500 mg im at the time of surgery. the timing of administration of progesterone in the neo-adjuvant setting is decided after collating data from large data-bases and randomised trials of screening suggesting that events at the time of surgery may alter the behavior of micro-metastases.

Eligibility criteria:
inclusion criteria: * unilateral operable palpable breast cancer exclusion criteria: * previous history of excision biopsy of the primary tumour * history of other epithelial/mesenchymal malignant tumours except basal cell carcinoma/squamous cell carcinoma (bcc/scc) of skin

Keywords: cancer of the breast neoplasm
study to assess the pharmacokinetics of cabozantinib (xl184) in hepatic impaired adult subjects

Conditions: Healthy; Hepatic Impairment

Summary: the main objective of this study is to compare the pharmacokinetics (pk) of a single oral 75 mg dose of cabozantinib in hepatic impaired adult subjects to healthy adult subjects. another objective is to assess the safety and tolerability of cabozantinib in these adult subjects.


Eligibility criteria:
inclusion criteria: * body weight must be ≥50 kg and \<130 kg with a bmi of ≥18 (kg/m2) and ≤36.0 (kg/m2). * must use acceptable forms of birth control during the course of the study and for 3 months following the single dose of study drug. * female subjects of childbearing potential must have a negative pregnancy test at screening and check-in. * must have adequate vital sign reads at screening and check-in. * must be able to comply with dietary and fluid restrictions required for the study

Keywords: normal healthy adult subjects adult subjects with hepatic impairment
effects of mobile game on life quality of cancer patients

Conditions: Breast Cancer

Summary: the purpose of this study is to determine whether functional games can be used to improve the adherence and quality of life of breast cancer patients with chemotherapy.


Eligibility criteria:
inclusion criteria: * diagnosed with breast cancer * receiving breast cancer chemotherapy * patients who are using a smartphone and agree to use a mobile functional game exclusion criteria: * patient with intellectual disability * diagnosed with congenital genetic disease * patients with a history of acquired brain injury such as cerebral palsy * developmental disorders, including autism * patients with language or learning disabilities

Keywords: breast cancer chemotherapy side effect mobile game
the use of near infrared spectroscopy (nirs) to estimate intracranial pressure (icp)

Conditions: Intracranial Hypertension

Summary: the aim of this study is to determine whether we can predict the intracranial pressure using near infra-red spectroscopy

the management of intracranial hypertension requires the presence of an intracranial pressure monitor. we are investigating whether the waveforms obtained from a near infrared spectroscopy device can predict what the intracranial pressure is non-invasively. * patients with intracranial hypertension who are intubated and ventilated in the icu will be recruited * we will record there intracranial pressure and systemic arterial pressure * recordings from the near infrared device will be recorded and analysed off-line * we will correlate the waveform tracings from near infrared spectroscopy and the arterial tracing

Eligibility criteria:
inclusion criteria: patients with an intracranial pressure monitor and arterial catheter who are admitted to the icu exclusion criteria: less than 18 years

Keywords: intracranial hypertension intracranial elastance
a video intervention to improve patient understanding of tumor genomic testing in patients with metastatic cancer

Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic Lung Carcinoma; Metastatic Malignant Solid Neoplasm; Prognostic Stage IV Breast Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8

Summary: this clinical trial tests whether a video intervention improves patient understanding of tumor genomic testing in patients with cancer that has spread to other parts of the body (metastatic). measuring how the video intervention affects patient understanding of tumor genomic testing in patients with metastatic cancer may help doctors provide patient-centered care by effectively communicating the importance of tumor genomic testing.

primary objective: i. to assess change in patient knowledge about tumor next generation sequencing (ngs) following exposure to the video. secondary objectives: i.to assess changes following exposure to the video, including; ia. genomic knowledge via the validated 10 true/false question survey (% correct out of 10). ib. 11-item trust in physician survey (tps) as a single tps score. ic. comparison of results in three patient cohorts: 1) metastatic breast cancer; 2) lung cancer; 3) metastatic cancer of unspecified type. exploratory objective: i. assess whether therapies prescribed as a result of tumor ngs achieved clinically favorable result through chart review. outline: patients participate in a video intervention session and complete questionnaires at baseline, after participating in the video intervention, and after receiving ngs results.

Eligibility criteria:
inclusion criteria: * patients must have biopsy-confirmed metastatic cancer * be \>= 18 years of age * be undergoing clinical tumor or circulating tumor deoxyribonucleic acid (dna) ngs exclusion criteria: * exclude patients who are not english- or spanish-speaking
vitamin d supplementation to obese chinese males

Conditions: Obesity; Insulin Resistance

Summary: hypothesis: oral supplementation of vitamin d can reduce hypersecretion of parathyroid hormone and insulin resistance in obese chinese males. protocol: weekly oral supplementation of 50,000 iu vitamin d (cholecalciferol) or eight weeks to the obese males compared with the normal-weight males. index measures were conducted at baseline and endpoint.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) ≥ 28kg/m2 or 18.5 ≤ bmi \< 24 (kg/m2) * non vegetarian han chinese and did not smoke, drink, nor take vitamin d supplements for \> 2 y * fasting serum glucose \< 7.0 mmol/l * serum glucose of 2 hr after 75 g oral glucose loading \< 11.1 mmol/l * normal functioning of liver and kidney evaluated by alkaline phosphatase, aspartate aminotransferase, creatinine, and uric acid exclusion criteria: * not match the above inclusion criteria * diagnosed as having any organic diseases were excluded

Keywords: vitamin d, oral supplementation, obese males